FORT LAUDERDALE, Fla., May 14, 2013 (GLOBE NEWSWIRE) -- Imaging Diagnostic Systems, Inc. (OTC:IMDS), a pioneer in laser breast imaging, announced today that it has received approval from the Ministry of Health in Kuwait to market and sell its innovative CTLM® in that country. Mareen Group Co., the exclusive distributor of CTLM® in Kuwait, has worked hard to achieve this significant accomplishment.
Ahmad Abdulrahman, General Manager of Mareen Group Co., comments: "We are honored and extremely pleased to achieve the approval of the Ministry of Health in Kuwait for the CTLM®. The CTLM® offers Kuwaiti women an imaging method without radiation, compression or contrast agents. In addition, the encouraging results of the published paper in the March 2013 edition of Clinical Imaging, a radiologist peer reviewed journal, shows the potential for this amazing modality. The results from that study, "CTLM® could distinguish benign lesions from malignant lesions and is not affected by breast density" are very important, especially regarding the dense breast population in Kuwait. Through upcoming installations, the women of Kuwait will hopefully benefit from this non-invasive and dignified option.
We are very excited and honored to announce the Kuwaiti Ministry of Health approval. This helps IDSI, through the efforts of Mareen Group Co., to expand the availability of CTLM® in the Middle East," said Linda Grable, CEO of Imaging Diagnostic Systems, Inc. "Mareen Group Co. is an established and successful distributor who will assist our efforts to increase worldwide use and adoption of CTLM®. Our success in receiving this approval in Kuwait should help us continue to drive the acceptance of the CTLM® worldwide; thereby assisting women's imaging needs."
Imaging Diagnostic Systems, Inc. is the developer of the CTLM® system; a revolutionary optical breast imaging device. Optical mammography is a diffuse optical tomography (DOT) technique that aims at detecting breast cancer. The CTLM® system utilizes patented continuous wave laser technology and computed algorithms to create 3D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. The CTLM® system has received certification and licenses to sell internationally through the following approvals; European CE marking, Health Canada, China SFDA, UL, ISO 13485:2003, FDA export certification. Marketing clearances pending are Mexico COFEPRIS and Russian GOST-R.
For more information, visit our website: www.imds.com
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Contact: Investor Relations, 954-581-9800
CONTACT: Investor Relations, 954-581-9800
Source:Imaging Diagnostic Systems, Inc.